Previous 10 | Next 10 |
NEWARK, Calif., March 12, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, today ...
NEWARK, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet need, today announce...
NEWARK, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, today ...
CymaBay Therapeutics (NASDAQ: CBAY ) is 4.8% lower after hours following a proposed public offering of shares . More news on: CymaBay Therapeutics, Healthcare stocks news, Stocks on the move Read more ...
NEWARK, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, today ...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on winning breakout selections over more than 5 years including 94 weeks of public weekly selections as part of this ongoing live forward-testing. Breakout Stock Portfolio 2019 results YTD All time total...
CymaBay Therapeutics (CBAY) Q4 2018 Earnings Conference Call February 28, 2019 4:30 PM ET Company Participants Dan Menold – Vice President-Finance Sujal Shah – Chief Executive Officer Pol Boudes – Chief Medical Officer Chuck McWherter – Chief Scienti...
Market Assessment 2019 is seen as the year of NASH in the biotech industry. The recent top-line data readout for Phase 3 investigative drug candidates, selonsertib by Gilead ( GILD ) and obeticholic acid by Intercept ( ICPT ), further demonstrated the complexity of NASH and the clinical chan...
CymaBay Therapeutics (NASDAQ: CBAY ): Q4 GAAP EPS of -$0.32 beats by $0.04 . More news on: CymaBay Therapeutics, Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
NEWARK, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced financial results and a corporate update for the ...
News, Short Squeeze, Breakout and More Instantly...
CymaBay Therapeutics Inc. Company Name:
CBAY Stock Symbol:
NASDAQ Market:
CymaBay Therapeutics Inc. Website:
Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for appr...
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.06% on the day to $32.49. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chr...
2024-03-12 10:45:01 ET UiPath Inc (PATH) PATH is trading UP for the last 5 days, and it at trading at $24.64 with volume of 4,269,666 and a one day change of $0.54 (2.25%). UiPath Inc has a 52-week low of 12.38 and a 52-week high of $27.87. The business's 50-day moving average price...